Today in History for Feb. 17: ...

The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.

Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would funnel crucial ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...